Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMEND (aprepitant) safety and effectiveness in Chinese patients receiving highly emetogenic chemotherapy
CTR20140536Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Nov 2014; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20140536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140536.